Elnaseeh Wafa, Yousif Elamin Mohamed, Bandar Alsliham Rahaf, Bandar Alotaibi Lujain, Abdulaziz Alaiban Hissa, Fouzy Kattan Mawadah, Khalid Alquraini Sadeem, Khalid Alkhateeb Ahmed, Ahmed Shaima ShamsEldeen KhalfAllah, Jamal Alamer Ziyad, Mohammed Alawdah Ahmed, Hamad Alhushayyish Mohammed, Jubayr Mohammed Altalhi Muhanna, Alhadidi Nojuod Fares Abdullah, Omar Alghamdi Albatul
College of Medicine, King Faisal University.
Faculty of Medicine, University of Khartoum.
Ann Med Surg (Lond). 2025 Mar 20;87(4):2324-2335. doi: 10.1097/MS9.0000000000003182. eCollection 2025 Apr.
Sinusitis is an inflammation of the paranasal sinuses and is commonly treated with antibiotics. The widely used antibiotics for this condition are macrolides, especially azithromycin. However, its effectiveness and side effects are still questionable compared to the other antibiotics. Therefore, this systematic review and meta-analysis assessed the efficacy and safety profile of azithromycin in sinusitis.
We adhered to PRISMA guidelines. A comprehensive literature review was performed to find out about randomized controlled trials concerning azithromycin compared with other antibiotics in sinusitis treatment. The main outcomes were the cure rate, pathogen eradication rate, and relapse rate. The secondary outcome was the adverse events rate.
Fourteen trials were considered for review, with a sample size of 4201 patients. The pooled analysis for included studies indicated a high cure rate (70.86%) and pathogen eradication rate (74.55%), as well as a low relapse rate (4.82%) and adverse events rate (14.33%) for azithromycin in treating sinusitis patients. The quality of the included studies was considered to be moderate. In a meta-analysis, azithromycin demonstrated superiority in the cure rate to other antibiotics in the study but no difference in pathogen eradication rate, relapse rate, or adverse events rate.
Our results showed promising efficacy and safety of azithromycin in the management of sinusitis patients. However, moderate heterogeneity among studies and a 14.33% rate of adverse effects, primarily gastrointestinal, indicate the importance of individualized treatment decisions. Further research is needed to address variability and optimize its clinical application.
鼻窦炎是鼻窦的炎症,通常用抗生素治疗。用于这种病症的广泛使用的抗生素是大环内酯类,尤其是阿奇霉素。然而,与其他抗生素相比,其有效性和副作用仍存在疑问。因此,本系统评价和荟萃分析评估了阿奇霉素在鼻窦炎治疗中的疗效和安全性。
我们遵循PRISMA指南。进行了全面的文献综述,以找出关于阿奇霉素与其他抗生素在鼻窦炎治疗中比较的随机对照试验。主要结局是治愈率、病原体根除率和复发率。次要结局是不良事件发生率。
共纳入14项试验进行综述,样本量为4201例患者。纳入研究的汇总分析表明,阿奇霉素治疗鼻窦炎患者的治愈率(70.86%)和病原体根除率(74.55%)较高,复发率(4.82%)和不良事件发生率(14.33%)较低。纳入研究的质量被认为是中等的。在荟萃分析中,阿奇霉素在治愈率方面优于其他抗生素,但在病原体根除率、复发率或不良事件发生率方面没有差异。
我们的结果显示阿奇霉素在治疗鼻窦炎患者方面具有良好的疗效和安全性。然而,研究之间存在中等程度的异质性,且不良反应发生率为14.33%,主要是胃肠道反应,这表明个体化治疗决策的重要性。需要进一步研究以解决变异性问题并优化其临床应用。